Skip to Content
Merck

CD74 interacts with APP and suppresses the production of Abeta.

Molecular neurodegeneration (2009-10-24)
Shuji Matsuda, Yukiko Matsuda, Luciano D'Adamio
ABSTRACT

Alzheimer disease (AD) is characterized by senile plaques, which are mainly composed of beta amyloid (Abeta) peptides. Abeta is cleaved off from amyloid precursor protein (APP) with consecutive proteolytic processing by beta-secretase and gamma-secretase. Here, we show that CD74, the invariant chain of class II major histocompatibility complex, interacts with APP and serves as a negative regulator of Abeta. CD74 resembles other APP interacters such as BRI2 and BRI3, since all of them reduce the level of Abeta. However, unlike BRIs, CD74 does not reduce the secretion of sAPPalpha or sAPPbeta. Interestingly, in HeLa cells, over expression of CD74 steers APP, but not Notch, to large vacuoles created by CD74. Taken together, we propose that CD74 inhibits Abeta production by interacting with and derailing normal trafficking of APP.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-APP A4 Antibody, a.a. 66-81 of APP {NT}, clone 22C11, clone 22C11, Chemicon®, from mouse
Millipore
ANTI-FLAG® M2 Affinity Gel, purified immunoglobulin, buffered aqueous glycerol solution
Sigma-Aldrich
ANTI-FLAG® M2 antibody, Mouse monoclonal, 1.0-1.2 mg/mL, clone M2, affinity isolated antibody, buffered aqueous solution (50% glycerol, 10 mM sodium phosphate, and 150 mM NaCl, pH 7.4)